Linked Life Data

19442208

Source:http://linkedlifedata.com/resource/pubmed/id/19442208

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-5-15
pubmed:abstractText
The voltage-dependent N-type calcium channel (Ca(v)2.2), which is distributed in the nerve endings of the central and peripheral nerves, is known to be strongly associated with the pathological processes of cerebral ischemia and neuropathic pain. Ziconotide, the chemically synthesized version of the 25-residue peptide marine toxin omega-conotoxin MVIIA, has been approved as an analgesic drug for severe chronic pain treatment. A blockade of N-type calcium channels has been suggested for reducing the neuronal injury occurring from ischemia/reperfusion events. Therefore, many efforts have been made to develop systemically available small-molecule N-type calcium channel blockers thus far. This review focuses on the latest updates concerning small-molecule N-type calcium channel blockers as potential candidates for the next generation of therapeutics for neuropathic pain and ischemic stroke. The pharmacological advantages of N-type calcium channel blockers in these pathological states are also described.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1873-4294
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
377-95
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke.
pubmed:affiliation
Pharmaceutical Research Lab., Pharmaceutical Company, Ajinomoto Co., Inc. Kanagawa, 210-8681, Japan. takashia_yamamoto@ajinomoto.com
pubmed:publicationType
Journal Article, Review